CN116731218A - Mushroom polysaccharide extract and preparation method and application thereof - Google Patents
Mushroom polysaccharide extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN116731218A CN116731218A CN202310680940.9A CN202310680940A CN116731218A CN 116731218 A CN116731218 A CN 116731218A CN 202310680940 A CN202310680940 A CN 202310680940A CN 116731218 A CN116731218 A CN 116731218A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide extract
- mushroom polysaccharide
- composition
- mushroom
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application relates to a mushroom polysaccharide extract, a preparation method and application thereof. Specifically, the application provides a mushroom polysaccharide extract, which is prepared by the following steps: pulverizing mushroom, adding water, heating, boiling, extracting, filtering to obtain filtrate, concentrating the filtrate under reduced pressure, adding ethanol water solution into the concentrated solution, mixing, precipitating with ethanol, centrifuging, filtering, and drying the obtained precipitate to obtain mushroom polysaccharide extract. The mushroom polysaccharide extract can be used for improving intestinal microecology disorder, and the mushroom polysaccharide extract and xylitol can synergistically improve the content of bifidobacteria in intestinal tracts, and have a synergistic effect in improving intestinal microecology caused by antibiotics.
Description
Technical Field
The application relates to the field of medicines, in particular to a mushroom polysaccharide extract and a preparation method and application thereof.
Background
Intestinal beneficial bacteria such as bifidobacteria have beneficial health assistance, for example, bifidobacteria are used as physiological beneficial bacteria, and have various important physiological functions such as biological barrier, nutrition effect, anti-tumor effect, immunity enhancing effect, gastrointestinal tract function improvement, aging resistance and the like on human health. However, oral antibiotics tend to cause a decrease or imbalance in the content of intestinal beneficial bacteria such as bifidobacteria, which adversely affects the health of the human body, particularly in patients who require multiple oral antibiotics for disease treatment, which tends to cause other diseases to occur, thereby causing pain to the patient. However, there is a lack of a medicament in the prior art which is effective in ameliorating the imbalance of intestinal beneficial bacteria such as bifidobacteria caused by oral antibiotics.
Accordingly, there is a need in the art to develop a medicament that can effectively ameliorate the imbalance of intestinal beneficial bacteria such as bifidobacteria caused by oral antibiotics.
Disclosure of Invention
In view of the above, the present application provides a mushroom polysaccharide extract, which can be useful for improving intestinal dysbiosis.
The first aspect of the application provides a mushroom polysaccharide extract, which is prepared by the following steps:
pulverizing mushroom, adding water, heating, boiling, extracting, filtering to obtain filtrate, concentrating the filtrate under reduced pressure, adding ethanol water solution into the concentrated solution, mixing, precipitating with ethanol, centrifuging, filtering, and drying the obtained precipitate to obtain mushroom polysaccharide extract.
Further, the mushrooms are mushrooms.
Further, in the aqueous ethanol solution, the volume fraction of ethanol is 85-100%, preferably 90-100%, preferably 95%.
Further, the method comprises the steps of:
pulverizing 4-6g of mushroom, adding 250-350g of water, heating, boiling, extracting for 3-5 hours, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to 25-35ml, adding 90-110ml of 93-97% ethanol water solution into the concentrated solution, mixing uniformly, precipitating with ethanol at 3-5 ℃, centrifuging, filtering, drying the obtained precipitate, and obtaining the mushroom polysaccharide extract.
Further, the method comprises the steps of:
pulverizing 5g of mushroom, adding 300g of water, heating, boiling, extracting for 4 hours, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to 30ml, adding 100ml of 95% ethanol water solution into the concentrated solution, uniformly mixing, carrying out alcohol precipitation at 4 ℃ for 24 hours, centrifuging, filtering, drying the obtained precipitate, and obtaining the mushroom polysaccharide extract.
In a second aspect, the present application provides a composition comprising a mushroom polysaccharide extract according to the first aspect of the present application and xylitol.
Further, the weight ratio of the mushroom polysaccharide extract to the xylitol is 1:1-20, preferably 1:1-10, preferably 1:3-7, preferably 1:5.
Further, the composition is a composition for improving intestinal dysbiosis.
Further, the composition is a pharmaceutical composition, a health-care product composition or a food composition.
Further, the composition also comprises a pharmaceutically, health-care product or food acceptable carrier.
Further, the formulation of the composition is an oral preparation or an injection preparation.
Further, the composition is a solid preparation or a liquid preparation.
In a third aspect, the application provides the use of a mushroom polysaccharide extract according to the first aspect of the application or a composition according to the second aspect of the application for the preparation of a medicament, a health product or a food for improving intestinal dysbiosis.
Further, the intestinal dysbiosis includes intestinal dysbiosis caused by oral administration of antibiotics.
Further, the intestinal dysbiosis includes a reduction in the beneficial intestinal bacteria content.
Further, the beneficial bacteria include bifidobacteria.
Further, the intestinal microecological disorder comprises a reduction in the content of bifidobacteria in the intestinal tract.
Further, the intestinal microecological disorder includes a decrease in intestinal bifidobacteria content caused by oral administration of antibiotics.
Further, the antibiotics include lincomycin hydrochloride and/or cefradine.
Further, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5. Preferably 1:1.
Further, the medicine, health-care product or food also comprises a carrier acceptable in pharmacy, health-care product or food.
Further, the dosage form of the medicine, the health care product or the food is an oral preparation.
Further, the medicine, health care product or food is a solid preparation or a liquid preparation.
Within the scope of the present application, the above-described technical features of the present application and technical features specifically described below may be combined with each other to constitute new or preferred technical solutions.
Detailed Description
The application develops a mushroom polysaccharide extract, which is prepared by a water extraction and alcohol precipitation method. The mushroom polysaccharide extract provided by the application can be used for improving intestinal microecological disturbance.
Fungus mushroom polysaccharide extract
The application provides a mushroom polysaccharide extract, which is prepared by the following steps:
pulverizing mushroom, adding water, heating, boiling, extracting, filtering to obtain filtrate, concentrating the filtrate under reduced pressure, adding ethanol water solution into the concentrated solution, mixing, precipitating with ethanol, centrifuging, filtering, and drying the obtained precipitate to obtain mushroom polysaccharide extract.
Further, the mushrooms are mushrooms.
As used herein, the latin academy of lentinus edodes is Lentinula edodes.
Typically, the method comprises the steps of:
pulverizing 5g of mushroom, adding 300g of water, heating, boiling, extracting for 4 hours, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to 30ml, adding 100ml of 95% ethanol water solution into the concentrated solution, uniformly mixing, carrying out alcohol precipitation at 4 ℃ for 24 hours, centrifuging, filtering, drying the obtained precipitate, and obtaining the mushroom polysaccharide extract.
As used herein, "95% aqueous ethanol solution" refers to an aqueous solution having a volume fraction of 95% ethanol.
Specifically, the mushroom polysaccharide extract according to the application is as described in the first aspect of the application.
The application also provides application of the mushroom polysaccharide extract in preparing medicines, health products or foods for improving intestinal dysbiosis.
Composition and method for producing the same
The application provides a composition, which can comprise the mushroom polysaccharide extract and xylitol.
The weight ratio of the mushroom polysaccharide extract to the xylitol according to the present application may be 1:1-20, preferably 1:1-10, preferably 1:3-7, preferably 1:5.
As used herein, xylitol is given the english name xylitol.
The composition is preferably a pharmaceutical composition, a nutraceutical composition or a food composition. The composition of the application can also comprise a pharmaceutically, health-care product or food acceptable carrier.
As used herein, "pharmaceutically, nutraceutically or food acceptable carrier" means one or more compatible solid, semi-solid, liquid or gel fillers that are suitable for human or animal use, and must be of sufficient purity and sufficiently low toxicity. "compatibility" means that the components and active ingredients of the composition and their admixture with each other do not significantly reduce the efficacy of the drug.
It will be appreciated that in the present application, the pharmaceutically, nutraceutically or food acceptable carrier is not particularly limited, and may be selected from materials commonly used in the art, or may be prepared by conventional methods, or may be purchased from the market. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifying agents (e.g., tween), wetting agents (e.g., sodium lauryl sulfate), buffering agents, chelating agents, thickening agents, pH adjusting agents, transdermal enhancers, colorants, flavoring agents, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
The application also provides application of the composition in preparing medicines, health products or foods for improving intestinal dysbiosis.
The beneficial effects are that:
the application develops the mushroom polysaccharide extract which can be used for improving intestinal microecological disturbance, and the mushroom polysaccharide extract and xylitol can synergistically improve the content of intestinal bifidobacteria, so that the mushroom polysaccharide extract has a synergistic effect in improving intestinal microecological disturbance caused by antibiotics.
Those skilled in the art can, with the benefit of this disclosure, suitably modify the process parameters to achieve this. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present application. While the methods and applications of this application have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this application, without departing from the spirit or scope of the application.
The application will be further illustrated with reference to specific examples.
Example 1
1. Preparation of lentinan extract
Pulverizing 5g Lentinus Edodes, adding 300g water, boiling for 4 hr, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to 30ml, adding 100ml 95% ethanol water solution into the concentrated solution, mixing, precipitating with ethanol at 4deg.C for 24 hr, centrifuging, filtering, and drying the obtained precipitate to obtain lentinan extract.
2. Effect investigation
The antibiotic mixed solution containing lincomycin hydrochloride and cefradine was administered to SD rats by gavage (the dose of lincomycin hydrochloride was 1g/kg. Bw. Times, the dose of cefradine was lg/kg. Bw. Times), 2 times a day, and after 4 consecutive days of administration, antibiotic-induced intestinal flora-deregulated rats were constructed. Rats with antibiotic-induced dysbacteriosis were randomly divided into experimental groups 1-4, while rats untreated with antibiotic administration were selected as a control group to which physiological saline was administered. The antibiotic-induced intestinal dysregulated rats of experimental groups 1-4 and the normal rats of the control group were administered by gavage, respectively, as follows:
control group: physiological saline;
experiment group 1: physiological saline;
experiment group 2: lentinan extract (at a dose of 0.02g/kg. Bw);
experiment group 3: xylitol (at a dose of 0.1g/kg. Bw);
experiment group 4: lentinan extract (at a dose of 0.02g/kg. Bw) and xylitol (at a dose of 0.1g/kg. Bw).
Each group of rats was continuously dosed for 3 days, 1 dose per day, and after 24 hours after the dosing on day 3, feces from the ileocecum of each group of rats were aseptically collected, and the values of the number of Colony Forming Units (CFU) of bifidobacteria per gram of wet weight of feces were calculated by colony morphology and smear analysis using Blb medium for bifidobacteria culture, whereby the content of bifidobacteria in the intestinal tracts of each group of rats was examined, and the results are shown in table 1.
Table 1 content of bifidobacteria in the intestinal tract of rats of each group (1 g CFU /g)
| Group of | Bifidobacterium strain |
| Control group | 8.86±0.46 |
| Experiment group 1 | 6.43±±0.21 |
| Experiment group 2 | 7.06+0.24 |
| Experiment group 3 | 7.32±0.37 |
| Experiment group 4 | 8.48±0.45 |
Table 1 shows that the bifidobacterium content of experimental group 1 is significantly smaller than that of control group, indicating that the construction of antibiotic-induced dysbacteriosis in rats is successful. The bifidobacterium content of the experimental group 2 is obviously higher than that of the experimental group 1, which shows that the lentinan extract can improve the content of the bifidobacterium in the intestinal tract so as to improve intestinal microecological disorder caused by antibiotics, and the comparison of the experimental groups 1-4 shows that the lentinan extract and xylitol can synergistically improve the content of the bifidobacterium in the intestinal tract, thereby having a synergistic effect in improving the intestinal microecology caused by antibiotics.
The foregoing is merely a preferred embodiment of the present application and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present application, which are intended to be comprehended within the scope of the present application.
While the application has been described in terms of one embodiment, it should be noted that modifications could be made without departing from the principles of the application, which would be apparent to those skilled in the art, would also be considered to be within the scope of the application.
Claims (9)
1. The mushroom polysaccharide extract is characterized by being prepared by the following steps:
pulverizing mushroom, adding water, heating, boiling, extracting, filtering to obtain filtrate, concentrating the filtrate under reduced pressure, adding ethanol water solution into the concentrated solution, mixing, precipitating with ethanol, centrifuging, filtering, and drying the obtained precipitate to obtain mushroom polysaccharide extract.
2. The mushroom polysaccharide extract of claim 1, wherein said method comprises the steps of:
pulverizing 4-6g of mushroom, adding 250-350g of water, heating, boiling, extracting for 3-5 hours, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to 25-35ml, adding 90-110ml of 93-97% ethanol water solution into the concentrated solution, mixing uniformly, precipitating with ethanol at 3-5 ℃, centrifuging, filtering, drying the obtained precipitate, and obtaining the mushroom polysaccharide extract.
3. A composition comprising the mushroom polysaccharide extract of claim 1 and xylitol.
4. A composition according to claim 3, wherein the weight ratio of the mushroom polysaccharide extract to the xylitol is 1:1-20, preferably 1:1-10, preferably 1:3-7, preferably 1:5.
5. The composition of claim 3, wherein the composition is a pharmaceutical composition, a nutraceutical composition, or a food composition.
6. The composition of claim 3, further comprising a pharmaceutically, nutraceutically or food acceptable carrier.
7. Use of a mushroom polysaccharide extract according to claim 1 or a composition according to claim 3 for the preparation of a medicament, a health product or a food for improving intestinal dysbiosis.
8. The use according to claim 7, wherein the intestinal dysbiosis comprises an intestinal dysbiosis caused by oral administration of an antibiotic.
9. The use according to claim 7, wherein the intestinal dysbiosis comprises a reduction in intestinal bifidobacteria content caused by oral administration of an antibiotic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310680940.9A CN116731218A (en) | 2023-06-09 | 2023-06-09 | Mushroom polysaccharide extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310680940.9A CN116731218A (en) | 2023-06-09 | 2023-06-09 | Mushroom polysaccharide extract and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116731218A true CN116731218A (en) | 2023-09-12 |
Family
ID=87903896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310680940.9A Pending CN116731218A (en) | 2023-06-09 | 2023-06-09 | Mushroom polysaccharide extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116731218A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546889A (en) * | 2014-12-04 | 2015-04-29 | 无限极（中国）有限公司 | Application of lentinan in preparing medicine, healthcare product and food in treating or preventing disease caused by enteric flora disturbance |
| CN106617080A (en) * | 2015-10-30 | 2017-05-10 | 无限极（中国）有限公司 | Application of lentinan in preparation of healthcare food with intestinal flora regulating function |
| CN107198101A (en) * | 2017-06-16 | 2017-09-26 | 王晓彬 | A kind of ease constipation road steamed bun powder and preparation method thereof and purposes |
| CN107647251A (en) * | 2017-08-24 | 2018-02-02 | 太和县三九药业有限公司 | A kind of preparation method of compound edible mushroom nutrient chewable tablet |
| CN110256598A (en) * | 2019-07-17 | 2019-09-20 | 武汉工程大学 | A kind of preparation method of difference bioactivity lentinan |
| CN112870253A (en) * | 2021-01-20 | 2021-06-01 | 益家元品实业（厦门）有限公司 | Flos puerariae extract for improving intestinal micro-ecological imbalance |
| CN114191447A (en) * | 2020-09-18 | 2022-03-18 | 华熙生物科技股份有限公司 | Application of hyaluronic acid and salt thereof in improving intestinal flora disorder and composition thereof |
| CN114698852A (en) * | 2022-04-20 | 2022-07-05 | 成都凝创合炬生物科技集团有限公司 | Multifunctional synbiotic composition with antioxidant effect and preparation |
-
2023
- 2023-06-09 CN CN202310680940.9A patent/CN116731218A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546889A (en) * | 2014-12-04 | 2015-04-29 | 无限极（中国）有限公司 | Application of lentinan in preparing medicine, healthcare product and food in treating or preventing disease caused by enteric flora disturbance |
| CN106617080A (en) * | 2015-10-30 | 2017-05-10 | 无限极（中国）有限公司 | Application of lentinan in preparation of healthcare food with intestinal flora regulating function |
| CN107198101A (en) * | 2017-06-16 | 2017-09-26 | 王晓彬 | A kind of ease constipation road steamed bun powder and preparation method thereof and purposes |
| CN107647251A (en) * | 2017-08-24 | 2018-02-02 | 太和县三九药业有限公司 | A kind of preparation method of compound edible mushroom nutrient chewable tablet |
| CN110256598A (en) * | 2019-07-17 | 2019-09-20 | 武汉工程大学 | A kind of preparation method of difference bioactivity lentinan |
| CN114191447A (en) * | 2020-09-18 | 2022-03-18 | 华熙生物科技股份有限公司 | Application of hyaluronic acid and salt thereof in improving intestinal flora disorder and composition thereof |
| CN112870253A (en) * | 2021-01-20 | 2021-06-01 | 益家元品实业（厦门）有限公司 | Flos puerariae extract for improving intestinal micro-ecological imbalance |
| CN114698852A (en) * | 2022-04-20 | 2022-07-05 | 成都凝创合炬生物科技集团有限公司 | Multifunctional synbiotic composition with antioxidant effect and preparation |
Non-Patent Citations (2)
| Title |
|---|
| 史奎雄: "医学营养学", vol. 1, 30 September 1998, 上海交通大学出版社, pages: 106 * |
| 潘道东等: "功能性食品添加剂", vol. 1, 31 January 2006, 中国轻工业出版社, pages: 106 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103750324B (en) | A kind of milk basic protein Hericium erinaceus powder composite sheet | |
| EP1448215B1 (en) | Use of laminarin in the treatment of cancer | |
| EP2098240B1 (en) | Agent for promoting healing of living body | |
| EP3225234A1 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| JP2013531071A (en) | Antiviral properties of Aloe vera and acquired immune deficiency syndrome (AIDS) treatment | |
| DE69100314T2 (en) | Treatment of Clostridium difficile diarrhea and pseudomembrane colitis. | |
| JP4831711B1 (en) | Anti-Candida fungi and prophylactic and / or therapeutic agents for candidiasis comprising Tamogitake extract as an active ingredient | |
| CN112870253A (en) | Flos puerariae extract for improving intestinal micro-ecological imbalance | |
| CN112168855A (en) | A composition for preparing intestinal tract and treating constipation | |
| CN107648297B (en) | Lonicera fulvidraco extract, preparation containing extract and application of extract in field of medicine | |
| DE69031694T3 (en) | Glutamine for the treatment of impaired immunity | |
| CN108056928A (en) | A kind of buccal cavity gel of the rare saponin(e containing Radix Notoginseng and preparation method thereof | |
| CN1401365A (en) | Chinese health medicine | |
| CN1169839C (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN116731218A (en) | Mushroom polysaccharide extract and preparation method and application thereof | |
| EP2486931B1 (en) | Therapeutic agent for influenza virus infectious diseases | |
| JP5187935B2 (en) | Wound healing promoting composition containing Rahan fruit extract and application method | |
| CN112472733A (en) | A flos Puerariae Lobatae extract for promoting calcium oral absorption | |
| CN112451533A (en) | Composition for improving side effect of oral intestinal tract cleaning agent | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| CN114617916B (en) | Loquat leaf extract and application thereof in health care | |
| CN1168462C (en) | An oral solution capable of lowering blood fat and improving symptoms of myocardial ischemia and myocardial infarction | |
| US3894153A (en) | Method of medical treatment of asthma | |
| CN104622934A (en) | Novel application of olive leaf crude extract in preparation of drugs for treating sphagitis | |
| CN108938832A (en) | A kind of traditional Chinese medicine oral liquid and preparation method thereof preventing and treating grice diarrhoea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |